Emilio Xavier Esposito
Overview
Explore the profile of Emilio Xavier Esposito including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pulugulla S, Workman R, Rutter N, Yang Z, Adamik J, Lupish B, et al.
J Biol Chem
. 2018 Oct;
293(52):19942-19956.
PMID: 30355733
We previously reported that transcription of the human gene, encoding the proinflammatory cytokine interleukin 1β, depends on long-distance chromatin looping that is stabilized by a mutual interaction between the DNA-binding...
2.
Sharma S, Yip C, Esposito E, Sharma P, Simon M, Abel-Santos E, et al.
J Med Chem
. 2018 Jul;
61(15):6759-6778.
PMID: 30004695
Clostridium difficile infections (CDI), particularly those caused by the BI/NAP1/027 epidemic strains, are challenging to treat. One method to address this disease is to prevent the development of CDI by...
3.
Lin F, Esposito E, Tseng Y
Front Pharmacol
. 2018 Mar;
9:96.
PMID: 29556192
We previously described a structure-based fragment hopping for lead optimization using a pre-docked fragment database, "LeadOp," that conceptually replaced "bad" fragments of a ligand with "good" fragments while leaving the...
4.
Berberich J, Stouch T, Manepalli S, Esposito E, Madura J
Chem Res Toxicol
. 2016 Aug;
29(9):1534-40.
PMID: 27494215
There is a pressing need for new therapeutics to reactivate covalently inactivated acetylcholinesterase (AChE) due to exposure to organophosphorus (OP) compounds. Current reactivation therapeutics (RTs) are not broad-spectrum and suffer...
5.
Esposito E, Hopfinger A, Shao C, Su B, Chen S, Tseng Y
Toxicol Appl Pharmacol
. 2015 Jul;
288(1):52-62.
PMID: 26200234
Carbon nanotubes have become widely used in a variety of applications including biosensors and drug carriers. Therefore, the issue of carbon nanotube toxicity is increasingly an area of focus and...
6.
Felton L, Popescu C, Wiley C, Esposito E, Lefevre P, Hopfinger A
AAPS PharmSciTech
. 2014 Apr;
15(4):872-81.
PMID: 24718709
The objective of this research was to investigate physicochemical properties of an active pharmaceutical ingredient (API) that influence cyclodextrin complexation through experimental and computational studies. Native β-cyclodextrin (B-CD) and two...
7.
Esposito E, Stouch T, Wymore T, Madura J
Chem Res Toxicol
. 2014 Jan;
27(1):99-110.
PMID: 24443939
The inactivation of acetylcholinesterase (AChE) by organophosphorus agent (OP) compounds is a serious problem regardless of how the individual was exposed. The reactivation of OP-inactivated AChE is dependent on the...
8.
Dunbar Jr J, Smith R, Damm-Ganamet K, Ahmed A, Esposito E, Delproposto J, et al.
J Chem Inf Model
. 2013 Apr;
53(8):1842-52.
PMID: 23617227
A major goal in drug design is the improvement of computational methods for docking and scoring. The Community Structure Activity Resource (CSAR) has collected several data sets from industry and...
9.
Chang C, Hsu M, Esposito E, Tseng Y
J Chem Inf Model
. 2013 Mar;
53(4):958-71.
PMID: 23464929
The traditional biological assay is very time-consuming, and thus the ability to quickly screen large numbers of compounds against a specific biological target is appealing. To speed up the biological...
10.
Shao C, Chen S, Su B, Tseng Y, Esposito E, Hopfinger A
J Chem Inf Model
. 2012 Dec;
53(1):142-58.
PMID: 23252880
Little attention has been given to the selection of trial descriptor sets when designing a QSAR analysis even though a great number of descriptor classes, and often a greater number...